Abstract
Two different doses of quinupristin/dalfopristin were compared with intravenous vancomycin with regard to the efficacy and safety in the treatment of catheter-related staphylococcal bacteremia. A total of 39 patients were enrolled from 13 centers. For all treated patients with a baseline pathogen, outcome was comparable for all antibiotic study regimens. Discontinuation of the antibiotic for an adverse clinical event occurred in 12% of patients receiving quinupristin/dalfopristin and in 15% of those receiving vancomycin. Quinupristin/dalfopristin may have the potential to serve as an alternative agent in the treatment of catheter-related staphylococcal bacteremia. However, larger prospective randomized trials are required.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Comparative Study
-
Randomized Controlled Trial
MeSH terms
-
Adult
-
Aged
-
Anti-Bacterial Agents / administration & dosage
-
Anti-Bacterial Agents / therapeutic use*
-
Bacteremia / drug therapy*
-
Bacteremia / etiology
-
Catheterization / adverse effects
-
Drug Administration Schedule
-
Drug Therapy, Combination / therapeutic use*
-
Female
-
Humans
-
Male
-
Middle Aged
-
Pilot Projects
-
Prospective Studies
-
Single-Blind Method
-
Staphylococcal Infections / drug therapy*
-
Staphylococcal Infections / etiology
-
Vancomycin / therapeutic use*
-
Virginiamycin / administration & dosage
-
Virginiamycin / analogs & derivatives*
-
Virginiamycin / therapeutic use
Substances
-
Anti-Bacterial Agents
-
Virginiamycin
-
quinupristin
-
Vancomycin
-
dalfopristin